Session # n/a

Increased utilization of multi-gene panel testing for hereditary cancer: overcoming initial barriers.

Multi-gene panels (MGP) for hereditary cancer susceptibility became commercially available in the United States in 2012. Both genetics and non-genetics providers experienced initial concerns regarding utility and implementation of MGP. However, research has demonstrated multiple benefits of MGP, such as a higher diagnostic yield. This study analyzes the utilization of MGP over a three-year period at a clinical diagnostic laboratory in the U.S.

• Authors: Emily Dalton; Kelly Fulk; Amal Yussuf; Rachel McFarland; Holly LaDuca; Jill Dolinsky
• Conference: ESHG 2016
• Date: Saturday, May 21, 2016 3:00pm - 4:00pm